<DOC>
	<DOCNO>NCT01282424</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety idelalisib patient previously treat indolent Non-Hodgkin Lymphoma ( iNHL ) refractory rituximab alkylating-agent-containing chemotherapy . The primary objective ass overall response rate . Eligible patient initiate oral therapy idelalisib start dose 150 mg take twice per day . Treatment idelalisib continue compliant patient long study still ongoing patient appear benefit treatment acceptable safety .</brief_summary>
	<brief_title>Efficacy Safety Study Idelalisib Subjects With Indolent B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Age ≥ 18 year Karnofsky performance score ≥ 60 ( Eastern Cooperative Oncology Group [ ECOG ] performance score 0 , 1 , 2 ) Histologically confirm diagnosis Bcell iNHL , histological subtype limit follow : Follicular lymphoma ( FL ) Small lymphocytic lymphoma ( SLL ) absolute lymphocyte count Lymphoplasmacytic lymphoma ( LPL ) , without associate Waldenstroms Macroglobulinemia ( WM ) Marginal zone lymphoma ( MZL ) ( splenic , nodal , extranodal ) Prior treatment ≥ 2 prior chemotherapybased immunotherapybased regimen iNHL Presence radiographically measurable lymphadenopathy extranodal lymphoid malignancy Prior treatment rituximab alkylating agent ( eg , bendamustine , cyclophosphamide , ifosfamide , chlorambucil , melphalan , busulfan , nitrosoureas ) iNHL Lymphoma refractory rituximab alkylating agent Discontinuation therapy treatment iNHL ≥ 3 week Visit 2 For men woman childbearing potential , willingness abstain sexual intercourse employ effective method contraception study drug administration followup period Willingness ability provide write informed consent comply protocol requirement Central nervous system leptomeningeal lymphoma Known histological transformation iNHL diffuse large Bcell lymphoma . History nonlymphoma malignancy except follow : adequately treat local basal cell squamous cell carcinoma skin , cervical carcinoma situ , superficial bladder cancer , localize prostate cancer , adequately treat Stage 1 2 cancer currently complete remission , cancer complete remission ≥ 5 year Evidence ongoing systemic bacterial , fungal , viral infection ( exclude viral upper respiratory tract infection ) time initiation study treatment Pregnancy breastfeed Ongoing alcohol drug addiction Known history druginduced liver injury , chronic active hepatitis B infection , chronic active hepatitis C infection , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , ongoing extrahepatic obstruction cause stone , cirrhosis liver , portal hypertension History prior allogeneic bone marrow progenitor cell solid organ transplantation Ongoing immunosuppressive therapy , include systemic corticosteroid . Patients may use topical inhaled corticosteroid . Prior therapy idelalisib Exposure another investigational drug within 3 week prior start study treatment . Concurrent participation another therapeutic treatment trial . Prior ongoing clinically significant illness , medical condition , surgical history , physical finding , ECG finding , laboratory abnormality , investigator 's opinion , could affect safety patient , alter absorption , distribution , metabolism excretion study drug , impair assessment study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>indolent Non-Hodgkin Lymphoma</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>iNHL</keyword>
	<keyword>NHL</keyword>
	<keyword>GS-1101</keyword>
	<keyword>CAL-101</keyword>
	<keyword>PI3K</keyword>
	<keyword>Phosphatidylinositol 3-kinase</keyword>
	<keyword>Follicular Lymphoma ( FL )</keyword>
	<keyword>Small lymphocytic lymphoma ( SLL )</keyword>
	<keyword>Lymphoplasmacytoid lymphoma ( LPL )</keyword>
	<keyword>Marginal zone lymphoma ( MZL )</keyword>
</DOC>